N/A N=44 Hospital-based Patient Navigation and Smoking Cessation
Smoking Cessation
Primary: Number of Participants With Prescription for an FDA-approved Smoking Cessation Medication — 9; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=46 Immediate Loading and Fully Guided Surgery: Single Implants
Osseointegration Failure of Dental Implant
Primary: Number of Participants With Implant Survival — 19; 25 participants
N/A N=162 KBTH-GIRHL Healthy Birth Weight Study: A Cross-Section
Infant, Small for Gestational Age · Infant, Low Birth Weight · Pregnancy
Primary: Birth Weight of Baby — 3033 grams
N/A N=12 Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus
Keratoconus
Primary: Number of Participants With Normal Vision — 8 Participants
N/A N=80 Effects of Obesity Treatments on Food Preferences and Metabolism
Obesity · Type 2 Diabetes Mellitus
Primary: Change in Energy Intake From Baseline — 500; 310; 482; 5 kcal
Phase 3 N=998 Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
Hypercholesterolemia
Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) — 71.6; 16.2; 0.2; 4.5 percentage of participants
N/A N=31 Correlation of Anal Acoustic Reflectometry Parameters With Degree of Rectal Intussusception and Prolapse
Pelvic Floor Disorders
Primary: Opening Pressure — 56.35; 39.01; 23.42 cmH20
Phase 4 N=120 Osteoarthritis Knee Pain Relief Study of 0.25% 920-CGS-200
Osteoarthritis, Knee
Primary: Percentage of Subjects With 50% or Greater Pain Score Reduction From Baseline to 24 Hours After First Dose of Study Drug Treatment. — 27.03; 20.0; 23.08; 20.0 percentage…
Phase 4 N=25 Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older
Carcinoma, Non-Small-Cell Lung · ErbB Receptors
Primary: Percentage of Participants Reporting an Adverse Event (AE) Leading to Dose Reduction of Afatinib — 32.0 Percentage
N/A N=21 Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.
Sleep Apnea, Obstructive · Hypertension, Pulmonary · Heart Failure
Primary: Pulmonary Artery Systolic Pressure. — 58.6; 62.7; 42.8; 57.5 mmHg
Phase 2 N=62 A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Primary: Number of Participants With Adverse Events — 6; 0; 3; 2 Participants
Phase 2 N=92 A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
Psoriasis Vulgaris · Plaque Psoriasis
Primary: Percentage of Participants Achieving Psoriasis Area and Severity Index ≥75% (PASI 75) Improvement — 4; 1; 0 Participants
Phase 2 N=54 Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Biliary Tract Cancer · Biliary Tract Neoplasms
Primary: Overall Response Rate (ORR) After 4 Cycles of Treatment — 22 percent
N/A N=3,194 Dispatcher-Activated Neighborhood Access Defibrillation and Cardiopulmonary Resuscitation
Out of Hospital Cardiac Arrest
Primary: Number of Participants Surviving at Hospital Discharge — 135; 216 Participants
N/A N=24 aeRobic Exercise and Cognitive Health
Alzheimer's Disease · Aging
Primary: Acceptability: Percentage of Sessions Completed by Enhanced Physical Activity Group — 99.2 Percentage of Sessions